The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.

<h4>Purpose</h4>Epigenetic alterations have been investigated as prognostic indicators in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. We present the results of a meta-analysis of the associations between RASSF1A promote...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong Jiang, Lin Cui, Wen-de Chen, Shi-hai Shen, Li-dong Ding
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ee14a746f73a411994b92e112ed749c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee14a746f73a411994b92e112ed749c3
record_format	dspace
spelling	oai:doaj.org-article:ee14a746f73a411994b92e112ed749c32021-11-18T07:18:23ZThe prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.1932-620310.1371/journal.pone.0036780https://doaj.org/article/ee14a746f73a411994b92e112ed749c32012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22615811/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Purpose</h4>Epigenetic alterations have been investigated as prognostic indicators in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. We present the results of a meta-analysis of the associations between RASSF1A promoter methylation status and both disease free survival (DFS) and overall survival (OS) in female breast cancer.<h4>Methods</h4>Eligible studies were identified through searching the PubMed, Web of Science and Embase databases. Studies were pooled and summary hazard ratios (HR) with corresponding confidence intervals (CIs) were calculated. Funnel plots were also carried out to evaluate publication bias.<h4>Results</h4>A total of 1795 patients from eight studies were included in the meta-analysis. There are eight studies which investigated DFS in 1795 cases. The relative hazard estimates ranged from 1.77-5.64 with a combined HR of 2.75 (95%CI 1.96-3.84). The HR of RASSF1A promoter methylation on DFS adjusted for other potential prognostic factors was 2.54 (95%CI 1.77-3.66). There has been five trials which analyzed the associations of RASSF1A promoter methylation status with OS in 1439 patients. The hazard estimates ranged from 1.21-6.90 with a combined random-effects estimates of 3.47 (95%CI 1.44-8.34). OS reported in multivariate analysis was evaluated in four series comprising 1346 cases and the summarized random-effects HR estimate was 3.35 (95%CI 1.14-9.85). Additionally, no publication bias was detected for both OS and DFS.<h4>Conclusion</h4>The results of this meta-analysis suggest that RASSF1A promoter hypermethylation confers a higher risk of relapse and a worse survival in patients with breast cancer. Large prospective studies are now needed to establish the clinical utility of RASSF1A promoter methylation.Yong JiangLin CuiWen-de ChenShi-hai ShenLi-dong DingPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 5, p e36780 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yong Jiang Lin Cui Wen-de Chen Shi-hai Shen Li-dong Ding The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
description	<h4>Purpose</h4>Epigenetic alterations have been investigated as prognostic indicators in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. We present the results of a meta-analysis of the associations between RASSF1A promoter methylation status and both disease free survival (DFS) and overall survival (OS) in female breast cancer.<h4>Methods</h4>Eligible studies were identified through searching the PubMed, Web of Science and Embase databases. Studies were pooled and summary hazard ratios (HR) with corresponding confidence intervals (CIs) were calculated. Funnel plots were also carried out to evaluate publication bias.<h4>Results</h4>A total of 1795 patients from eight studies were included in the meta-analysis. There are eight studies which investigated DFS in 1795 cases. The relative hazard estimates ranged from 1.77-5.64 with a combined HR of 2.75 (95%CI 1.96-3.84). The HR of RASSF1A promoter methylation on DFS adjusted for other potential prognostic factors was 2.54 (95%CI 1.77-3.66). There has been five trials which analyzed the associations of RASSF1A promoter methylation status with OS in 1439 patients. The hazard estimates ranged from 1.21-6.90 with a combined random-effects estimates of 3.47 (95%CI 1.44-8.34). OS reported in multivariate analysis was evaluated in four series comprising 1346 cases and the summarized random-effects HR estimate was 3.35 (95%CI 1.14-9.85). Additionally, no publication bias was detected for both OS and DFS.<h4>Conclusion</h4>The results of this meta-analysis suggest that RASSF1A promoter hypermethylation confers a higher risk of relapse and a worse survival in patients with breast cancer. Large prospective studies are now needed to establish the clinical utility of RASSF1A promoter methylation.
format	article
author	Yong Jiang Lin Cui Wen-de Chen Shi-hai Shen Li-dong Ding
author_facet	Yong Jiang Lin Cui Wen-de Chen Shi-hai Shen Li-dong Ding
author_sort	Yong Jiang
title	The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
title_short	The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
title_full	The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
title_fullStr	The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
title_full_unstemmed	The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
title_sort	prognostic role of rassf1a promoter methylation in breast cancer: a meta-analysis of published data.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/ee14a746f73a411994b92e112ed749c3
work_keys_str_mv	AT yongjiang theprognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT lincui theprognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT wendechen theprognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT shihaishen theprognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT lidongding theprognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT yongjiang prognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT lincui prognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT wendechen prognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT shihaishen prognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata AT lidongding prognosticroleofrassf1apromotermethylationinbreastcancerametaanalysisofpublisheddata
_version_	1718423700348338176

The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.

Ejemplares similares